Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy

Luca Mastrantoni(Università Cattolica del Sacro Cuore), Emilio Bria(Università Cattolica del Sacro Cuore), Fabio Puglisi(University of Udine), Noemi Maliziola(Università Cattolica del Sacro Cuore), Federica Miglietta(University of Padua), Sara Pilotto(University of Verona), Luisa Carbognin(Agostino Gemelli University Polyclinic), Gianluca Franceschini(Agostino Gemelli University Polyclinic), Michèle Milella(National Cancer Institute), Giovanni Scambia(Agostino Gemelli University Polyclinic), Ida Paris(Agostino Gemelli University Polyclinic), Valentina Guarneri(Istituto Oncologico Veneto), Letizia Pontolillo(Università Cattolica del Sacro Cuore), Alessandra Fabi(Agostino Gemelli University Polyclinic), Sergio Pannunzio(Università Cattolica del Sacro Cuore), Giampaolo Tortora(University of Naples Federico II), Lorenzo Gerratana(National Cancer Institute), Giovanna Garufi(Agostino Gemelli University Polyclinic), Fabio Marazzi(Agostino Gemelli University Polyclinic), Roberta Mazzeo(University of Udine), Antonella Palazzo(Agostino Gemelli University Polyclinic), Maria Vittoria Dieci(Istituto Oncologico Veneto), Antonio Franco(Stazione Zoologica Anton Dohrn), Diana Giannarelli(Agostino Gemelli University Polyclinic), Elena Di Monte(Università Cattolica del Sacro Cuore), Valentina Frescura(Università Cattolica del Sacro Cuore), Giulia Giordano(Agostino Gemelli University Polyclinic), Giorgia Arcuri(Università Cattolica del Sacro Cuore), Angelachiara Rotondi(Università Cattolica del Sacro Cuore), Armando Orlandi(Agostino Gemelli University Polyclinic)
npj Breast Cancer
February 5, 2025
10.1038/s41523-025-00727-w
Cited by 9

Related Papers

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724